TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers at Albert Einstein College of Medicine found that declining chaperone-mediated autophagy (CMA) impairs the body’s ability to clear senescent ‘zombie cells.’ Restoring CMA activity in mice reduced zombie cell buildup and lessened lung fibrosis severity. The study suggests a new therapeutic strategy involving CMA activators rather than solely relying on senolytic drugs.
The study, led by Ana Maria Cuervo, M.D., Ph.D., a distinguished professor of developmental and molecular biology, investigated why senescent cells become increasingly difficult to eliminate as organisms age. Senescent cells are living cells that have stopped dividing but remain in tissues, contributing to chronic inflammation and age-related diseases. The researchers found that declining CMA activity impairs both the senescent cells themselves and the macrophages, a type of immune cell responsible for removing them. In experiments with mice, genetically altering macrophages to lack CMA resulted in slower wound healing and greater accumulation of zombie cells at injury sites.
When researchers induced senescence in fibroblasts from young and old mice, they observed distinct differences in CMA activity. Cells from young mice increased their CMA activity as they became senescent, allowing them to manage internal waste. In contrast, cells from older mice failed to increase their already low CMA activity. This failure caused undigested toxic substances to accumulate within the senescent cells, which were then secreted into the surrounding tissue. According to the study, these secretions made nearby healthy cells more likely to become senescent and interfered with the macrophages’ ability to recognize and engulf the zombie cells.
To test a potential intervention, the team used CA77.1, a small-molecule compound previously developed to activate CMA. In aged mice, five months of daily oral treatment with CA77.1 reduced the buildup of senescent cells in several organs and decreased signs of inflammation and fibrosis. In separate experiments, treating macrophages isolated from aged mice with CA77.1 restored their ability to engulf particles to levels comparable to those seen in macrophages from young mice. The researchers also analyzed human lung tissue, which provided evidence that these mechanisms may be relevant to human diseases such as idiopathic pulmonary fibrosis (IPF).
This research shifts the focus of senescence research from simply killing zombie cells to restoring the body’s natural clearance mechanisms. While senolytic drugs designed to eliminate senescent cells have been a major area of study, the new findings suggest that testing these drugs in cells from young animals may not accurately reflect their efficacy in older bodies. By highlighting the role of CMA in both the senescent cells and the immune system, the study points to a dual-action therapeutic approach. Activating CMA appears to reduce the harmful secretions of zombie cells while simultaneously enhancing the immune system’s ability to remove them. This could lead to treatments that address the root cause of age-related inflammation rather than just the symptoms, potentially offering new avenues for treating conditions like fibrosis, neurodegeneration, and metabolic disorders.
As an affiliate, we earn on qualifying purchases.
Declining Cellular Recycling Mechanisms
Chaperone-mediated autophagy (CMA) is a selective cellular recycling process where specialized chaperone molecules target damaged or unnecessary proteins for digestion. Dr. Cuervo, a leading authority on CMA, has previously established that CMA activity declines with age. Earlier research showed that reduced CMA allows cellular waste to accumulate in neurons and other cells, contributing to Alzheimer’s disease, atherosclerosis, and diabetes. Senescent cells, or zombie cells, are not always harmful; during wound healing, they release substances that recruit other cells for tissue repair. Normally, macrophages clear these cells after repair is complete. However, as CMA activity drops, this clearance process falters, allowing senescent cells to persist and disrupt healthy tissue function. The new study builds on this foundation by linking the failure of CMA in macrophages directly to the inability to clear senescent cells in aged tissues.
“The new findings suggest that testing these drugs in cells taken from young animals and made senescent in the laboratory may not fully capture how they will work in older bodies.”
— Study authors
senescent cell clearance supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Application and Long-Term Safety
While the study provides strong evidence in mice and analyzes human lung tissue, it is not yet clear how effectively the CA77.1 compound or similar CMA activators will work in humans. The research primarily focused on lung fibrosis and wound healing, so the extent to which this mechanism applies to other age-related diseases, such as neurodegeneration or cardiovascular disease, remains to be fully mapped. Additionally, the long-term safety and side effects of chronically activating CMA in humans have not been established. The transition from animal models to clinical trials involves significant regulatory and biological hurdles, and the optimal dosage and treatment duration for human patients are still unknown.
As an affiliate, we earn on qualifying purchases.
Clinical Trials and Compound Refinement
The next steps involve further preclinical testing to refine the CA77.1 compound and assess its efficacy in other disease models. Researchers will likely seek to initiate clinical trials to evaluate the safety and effectiveness of CMA activators in human patients, particularly those with idiopathic pulmonary fibrosis or other conditions linked to senescence. Future studies may also explore combination therapies, pairing CMA activators with existing senolytic drugs to enhance clearance rates. Scientists will continue to investigate the specific molecular pathways through which CMA influences macrophage function to identify more precise drug targets.
lung fibrosis treatment supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are zombie cells?
Zombie cells, formally known as senescent cells, are cells that have stopped dividing but remain alive in tissues. They often secrete inflammatory substances that can damage surrounding healthy cells and contribute to age-related diseases.
What is chaperone-mediated autophagy (CMA)?
CMA is a cellular recycling process where specific proteins are targeted by chaperone molecules and sent to lysosomes for digestion. It helps cells remove damaged or unnecessary proteins, maintaining cellular health.
How does the CA77.1 compound work?
CA77.1 is a small-molecule compound that activates CMA. In the study, it helped reduce the accumulation of senescent cells and improved the ability of immune cells to clear them in aged mice.
Is this treatment available for humans?
No, the treatment is currently in the preclinical research stage. While the results in mice are promising, clinical trials are needed to determine safety and efficacy in humans.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
